EARLY MORTALITY IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS: A POOLED ANALYSIS OF TWO LARGE RANDOMIZED PHASE III TRIALS